Would you administer postoperative adjuvant atezolizumab or chemotherapy for patients with locally advanced NSCLC and pathological residual disease following neoadjuvant nivolumab/chemotherapy and surgical resection?  

This is an excellent question. First, I would encourage all to check out some wonderful thoughts by Dr. @Halmos in two separate questions regarding perioperative NSCLC here and here. There are additional insights in this question as well. As of now, we do not have firm data on what, if any...